Research Use Only - Not for human consumption. 18+ only.

Leuphasyl vs Syn-Ake

Evidence-based comparison · Updated 2026

Summary

Leuphasyl and Syn-Ake both target expression wrinkles by inhibiting acetylcholine activity at the neuromuscular junction, but Leuphasyl mimics enkephalins and is noted for synergy with Argireline, while Syn-Ake mimics snake venom peptide waglerin-1 and is often marketed as a standalone Botox alternative. Choose Leuphasyl when combining with Argireline in a multi-peptide formula; choose Syn-Ake when seeking a single-peptide muscle-relaxing ingredient.

Side-by-Side Comparison

LeuphasylSyn-Ake
EvidenceDGrade DTheoretical or in-vitro only; no meaningful independent human evidenceDGrade DTheoretical or in-vitro only; no meaningful independent human evidence
RegulatoryResearch OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use onlyResearch OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only
Benefits
  • +Reduces muscle contraction
  • +Decreases wrinkle depth
  • +Synergistic with Argireline
  • +Targets expression lines
  • +Safe for topical use
  • +Relaxes facial muscles
  • +Reduces wrinkle depth
  • +Alternative to Botox
  • +Smooths expression lines
  • +Safe for sensitive skin
Dosage2-5% % — Daily topical2-4% % — Daily topical
RouteTopicalTopical
CategoryCosmetic & TopicalCosmetic & Topical

Full research page

Leuphasyl →

Full research page

Syn-Ake →

Which Should You Choose?

Both peptides inhibit acetylcholine signaling to reduce facial muscle contractions, but they do so through distinct receptor interactions: Leuphasyl acts via enkephalin-mimicking pathways while Syn-Ake binds directly to nicotinic acetylcholine receptors, giving each a different formulation context.

Choose Leuphasyl when:

  • +You are formulating a multi-peptide serum that already includes Argireline, since Leuphasyl is specifically noted for synergistic efficacy with Argireline.
  • +You want a peptide targeting the upstream inhibition of acetylcholine secretion rather than direct receptor blockade.
  • +Your formulation strategy prioritizes combining complementary mechanisms across several peptides rather than relying on a single high-concentration ingredient.

Choose Syn-Ake when:

  • +You want a single-ingredient muscle-relaxing peptide that functions as a standalone Botox-alternative concept in a simpler formula.
  • +Your target consumer or formulation brief emphasizes the 'snake venom' positioning, which has strong consumer recognition in anti-aging cosmetics.
  • +You are formulating for sensitive skin where a minimal active ingredient list is preferred, as Syn-Ake is noted for tolerability on sensitive skin.

Stacking Leuphasyl and Syn-Ake is reported in cosmetic formulation contexts as potentially additive since they act on overlapping but mechanistically distinct points in the acetylcholine signaling pathway, though robust clinical data confirming enhanced efficacy from this specific combination remains limited.

Frequently Asked Questions

Can Leuphasyl and Syn-Ake be used together in the same formula, and is there a risk of over-inhibiting muscle activity?⌄
Both peptides act on neuromuscular acetylcholine signaling, so combining them is theoretically aimed at additive wrinkle reduction. However, topical peptides have limited and variable skin penetration, making true over-inhibition of muscle activity unlikely at cosmetic concentrations. No published clinical data currently confirms either enhanced efficacy or adverse interaction from their combination. Formulators typically include both at low individual concentrations when stacking.
Which peptide shows a faster visible effect: Leuphasyl or Syn-Ake?⌄
Neither peptide has been compared head-to-head in a published clinical trial measuring onset time. Syn-Ake studies have reported measurable reductions in wrinkle depth within 28 days of twice-daily application in manufacturer-commissioned research. Leuphasyl efficacy data is similarly limited to industry-sponsored studies, and no independent comparative timeline data exists. Both should be considered slow-onset topical actives relative to injectable neurotoxins.
How do Leuphasyl and Syn-Ake differ in their mechanism despite both targeting the neuromuscular junction?⌄
Leuphasyl mimics endogenous enkephalins and is proposed to inhibit the release of acetylcholine from the presynaptic neuron. Syn-Ake is modeled on waglerin-1 and is reported to act postsynaptically by binding to and blocking nicotinic acetylcholine receptors. This means Leuphasyl targets vesicle release while Syn-Ake targets receptor occupancy, representing two distinct intervention points on the same signaling pathway.
If a formula already contains Argireline, should Leuphasyl or Syn-Ake be added as the second neuromuscular peptide?⌄
Leuphasyl is the more evidence-supported choice in this context, as it is specifically described in research as synergistic with Argireline, and some studies have evaluated the Argireline-plus-Leuphasyl combination directly. Syn-Ake has not been studied in combination with Argireline in published literature. Adding Leuphasyl to an Argireline-containing formula represents a more mechanistically reasoned stacking decision based on currently available data.

Not sure which fits your research goals?

Use the Goal Finder

Answer 3 questions and get a personalised peptide recommendation ranked by evidence grade.

Find My Peptide →

More Comparisons

bpc 157 vs tb 500mots c vs semaglutidedsip vs melanotan iiretatrutide vs tirzepatidecjc 1295 vs ipamorelin